NVCT — Nuvectis Pharma Income Statement
0.000.00%
Last trade - 00:00- $218.36m
- $199.83m
Annual income statement for Nuvectis Pharma, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Total Operating Expenses | 0.01 | 12.9 | 19.2 | 22.9 | 19.8 |
| Operating Profit | -0.01 | -12.9 | -19.2 | -22.9 | -19.8 |
| Total Net Non Operating Interest Income / Expense | |||||
| Net Income Before Taxes | -0.01 | -12.9 | -19.1 | -22.3 | -19 |
| Net Income After Taxes | -0.01 | -12.9 | -19.1 | -22.3 | -19 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -0.01 | -12.9 | -19.1 | -22.3 | -19 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -0.01 | -12.9 | -19.1 | -22.3 | -19 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.041 | -52.8 | -1.51 | -1.43 | -1.11 |
| Dividends per Share |